SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant attention driven by strong community conviction in its GPS immunotherapy, with extended patient survival in the AML Phase 3 trial fueling expectations for a substantial revaluation. Investors are actively discussing the potential for a multi-billion dollar buyout and the mounting pressure on short sellers, given reports of high borrow fees and limited share availability. This positive sentiment highlights the perceived transformative potential of the company's cancer-fighting pipeline.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is experiencing heightened discussion amidst a generally bullish crypto market, with community members anticipating potential breakthroughs fueled by technical indicators and developments like LitVM. While some predict significant price movements and a supply shock, others express skepticism about its performance relative to other digital assets, noting its struggle to maintain gains.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending, fueled by its exceptionally active community passionately championing the "OG meme" narrative of Rage Comics as a foundational "meme reset" for an upcoming market cycle. This dedicated base is consistently building an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and leadership in the meme coin space. The community's fervent belief is in making memes great again by returning to their original, chaotic internet culture.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending as a multi-chain meme coin, attracting buzz for its organic community growth, deflationary burn mechanism, and expansion across ecosystems including Solana, Cronos, and Base. The community holds strong conviction, emphasizing its decentralized nature and potential for significant impact within the meme coin space, with discussions also noting upcoming staking opportunities.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending due to an active 'memecoin season' on its blockchain, which is generating intense community discussion around various new and established meme tokens like $CAW, $RAGE, and $WEEDCOIN. The community highlights Solana's ecosystem as a prime platform for these assets, leveraging its speed and low transaction fees to drive speculative interest and viral movements.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing robust bullish momentum, driven by significant ETF inflows and growing institutional interest, sparking community conversations about a potential supply shock. Many long-term holders are celebrating recent gains and anticipating further price action, with key discussions focusing on breaking resistance levels and the long-term impact of regulatory clarity and its utility in global finance.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is actively trending as the community links it to Elon Musk's Grok AI, championing it as Grok's official AI digital dog. This narrative, coupled with strong community belief and a vocal base, positions BYTE as a significant contender within the AI-themed meme coin sector, where supporters anticipate substantial growth.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is generating significant buzz due to its crucial role in the expanding AI agent economy, recently emphasized by its collaboration with Google Cloud for an Agentic Interop Summit. The community perceives it as a fundamentally strong and undervalued asset, highlighting its real-world adoption and notable resilience amidst broader market movements. Many investors are actively discussing its potential for substantial long-term growth as a foundational player in decentralized AI and autonomous systems.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is trending following its recent listing on Robinhood, significantly increasing its accessibility and visibility to a broader retail audience, alongside the positive community reaction to its Binance futures delisting which is seen as removing prior price suppression. Traders and investors are actively discussing XCN's substantial price momentum and the anticipated launch of the Goliath Mainnet, which promises institutional-grade financial infrastructure and ISO 20022 compatibility. This enthusiasm is set against a backdrop of broader crypto market optimism, with many believing XCN is positioning for future growth within an emerging altcoin season.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending amid increasing optimism for the broader space sector, fueled by its recent acquisition of national security tech firm SciTec and ongoing discussions about potential involvement in a major U.S. missile defense initiative known as "Golden Dome." The community is actively discussing the company's past successful lunar mission and its perceived undervaluation relative to peers, anticipating future launches and strategic partnerships to drive significant growth.

statis crypto Watchlist

Bitcoin

Ethereum

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 2,284,050 shares, an...

Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) have received an average recommendation of "Hold" from the five research firms that are covering the company, MarketBeat.com reports...

Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average - Should You Sell?

Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200-Day Moving Average - Here's What Happened...

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and...

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium Atossa Therapeutics Presents Four Clinical Trial Updates...

<ul class="summary-bullets"><li>The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease.</li><li>The program could become eligible for a Priority Review Voucher upon future approval.</li><li>Preclinical data remains encouraging, with the therapy not limited to exon-specific targeting.</li></ul>Shares of Atossa Therapeutics (ATOS) rose 10% on Thursday after the company said the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to its investigational therapy (Z)-Endoxifen for Duchenne Muscular Dystrophy.<h2 class="st-heading-2">Potential For Priority Review Voucher</h2>The company said the designation expands the program into rare pediatric neuromuscular disease and may qualify Atossa for a Priority Review Voucher (PRV) upon future approval.&nbsp;The Rare Pediatric Disease designation is reserved for serious or life-threatening conditions affecting individuals from birth to 18 years old. Atossa noted that FDA authority to award new vouchers may lapse unless renewed, with pending U.S. legislation seeking to extend the program through 2029.Janet Rea, Senior Vice President of Research and Development, said emerging preclinical data is encouraging and noted that (Z)-Endoxifen does not target specific genetic errors, potentially allowing broader applicability.<h2 class="st-heading-2">Last Week’s FDA Interaction</h2>Last week, Atossa completed a Type C meeting with the FDA to review regulatory strategy for advancing (Z)-Endoxifen across metastatic disease, neoadjuvant treatment and breast cancer risk-reduction settings. The FDA provided feedback on expedited regulatory pathways, clinical development design and endpoint strategy that the company said could support a streamlined registrational approach.CEO Steven Quay said the meeting allowed the company to incorporate FDA input into development planning and could shorten its regulatory timeline. Rea said the clinical program is now supported by data from nearly 800 participants enrolled across multiple trials.<h2 class="st-heading-2">Drug Targets Key Cancer Pathways</h2>(Z)-Endoxifen is a medicine designed to block and break down estrogen receptors, including in tumors that no longer respond to other hormone treatments. It also acts on another cancer-related pathway called protein kinase C beta 1.Atossa is developing an oral version of the drug that passes through the stomach without being changed. This prevents some of the active form from turning into an inactive form and helps keep the drug working as intended.Clinical studies in nearly 800 adults, including both healthy volunteers and people with breast cancer, have shown the drug to be well tolerated at doses up to 360 mg per day, with no maximum tolerated dose identified.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Atossa was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:974/145;" src="https://news.stocktwits-cdn.com/atos_ss_png_38ed63cfce.webp" alt="atos ss.png" width="974" height="145"><figcaption>ATOS sentiment and message volume as of December 11| Source: Stocktwits</figcaption></figure>One bullish user said compliance might still be achievable given Atossa’s current position, though they noted it would depend on the stock staying above $1 or on fresh fund inflows.<stembedurl>https://stocktwits.com/saruribbon/message/638865009</stembedurl>Another user said they were “100% confident we get fda fast track for p3 [phase 3].”&nbsp;<stembedurl>https://stocktwits.com/Mrwwonka/message/638864270</stembedurl><a href="https://stocktwits.com/symbol/ATOS">Atossa’s stock</a> has declined 3.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track

The FDA’s designation broadens Atossa’s development pathway in DMD and could make the program eligible for a Priority Review Voucher.

Equity

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen Atossa Therapeutics Announces Issuance of...

Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock

Ascendiant Capital Markets lifted their price objective on Atossa Genetics from $7.75 to $8.00 and gave the company a "buy" rating in a report on Monday...

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across...

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.07	--	--	N/A
Q3 '25	-$0.06	-$0.07	-7.69%	MISSED
Q2 '25	-$0.06	-$0.07	-21.74%	MISSED
Q1 '25	-$0.06	-$0.05	11.77%	BEAT
Q4 '24	-$0.06	-$0.04	36.84%	BEAT

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ATOS News

ATOSAtossa Therapeutics Inc